StockData

Aspire-Lakewood vs Soligenix

ASBP and SNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ASBP and SNGX compare

Aspire-Lakewood is the larger company, worth 1.9 times as much as Soligenix ($11.6M against $6.1M).

Soligenix scores higher on the StockData Score (6 against 2 for Aspire-Lakewood), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricASBPSNGX
Size and price
Market cap$11.6M$6.1M
Share price$8.30$0.281
Change, 1 year95.8%−79.5%
Change, 5 years–−99.9%
Beta (5Y)–2.38
Employees–14
StockData Score
Total score26 (better)
Valuation score11
Growth score00
Performance score00
Health score15 (better)
Dividend score00
Valuation
P/S119×–
P/B1.0×0.9× (better)
Profitability
Gross margin−25.0%–
Operating margin−7495%–
Net margin−11314%–
Return on equity−1032%−242% (better)
Financial health
Debt / equity–0.00
Interest coverage−0.8×–
Current ratio7.99 (better)2.77
Altman Z-score−0.10 (better)−35.09
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions–4.3%
Held by insiders1.4%0.69%
Short interest, % of float–0.31%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.